PFÄFFIKON, Switzerland, September 28, 2022 / B3C newswire / -- Pureos Partners announces the appointment of Dr. Veronica Gambillara Fonck as a Partner to its team, effective 1 October 2022. Veronica is a biotech entrepreneur with more than 15 years of experience in building and growing biotech companies developing new drugs against several diseases. She was one of the core members responsible for building GlycoVaxyn’s success and its acquisition by GSK in 2015, when she became CEO and co-founder of LimmaTech. Subsequently, she was the founder CEO of Glycoera, a biotech spin-off from LimmaTech and successfully financed the company with a large Series A round in November 2021.
Klaus Breiner, Dominik Escher and Martin Münchbach, Managing Partners of Pureos stated: “We are very excited to welcome Veronica as a new Partner at Pureos. As a long-term biotech entrepreneur, she brings deep operational experience to the fund from which many of our portfolio companies will be able to benefit a great deal.”
Veronica commented: “I look forward to joining the Pureos team. The current portfolio of Pureos comprises very exciting biotech companies. I am thrilled to be able to contribute to the expansion of the Pureos franchise, with both the current fund as well as future fund generations”.
For high resolution please click the image.
About Pureos Partners and Pureos Bioventures
Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.
Pureos Partners AG
Dr. Klaus Breiner
Dr. Dominik Escher
Dr. Martin Münchbach
Published by B3C newswire